Auriga Reiterates a 'Hold' on Salix Pharmaceuticals (SLXP); Q1 Tops Estimates, But Upside Priced In
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Auriga reiterates a 'Hold' on Salix Pharmaceuticals (NASDAQ: SLXP) price target of $51.00.
Analyst, Difei Yang, said, "Q1 results were stronger than expected, partially due to better demand of Xifaxan coupled with lower than expected R&D expenses. Our outlook for the full year has not changed. We think the shares are fairly valued at these levels, and would stay on the sidelines."
"Lower R&D expenses accounted for most of the upside surprises although we expect R&D expense to be higher in the latter quarters of 2012. Management also updated 2012 guidance, with revenue, R&D expense, and SG&A unchanged. The non-GAAP EPS was increased from $2.45 to $2.59 as a result of one time convertible note offering."
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $49.60 yesterday.
Analyst, Difei Yang, said, "Q1 results were stronger than expected, partially due to better demand of Xifaxan coupled with lower than expected R&D expenses. Our outlook for the full year has not changed. We think the shares are fairly valued at these levels, and would stay on the sidelines."
"Lower R&D expenses accounted for most of the upside surprises although we expect R&D expense to be higher in the latter quarters of 2012. Management also updated 2012 guidance, with revenue, R&D expense, and SG&A unchanged. The non-GAAP EPS was increased from $2.45 to $2.59 as a result of one time convertible note offering."
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $49.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon.com (AMZN) PT Raised to $215 at UBS
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- MarineMax (HZO) PT Lowered to $35 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
